Synapsoft logo
AI Insights from Disclosures
Searching...
ENCell Co., Ltd. 456070
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
ENCell Co., Ltd. has two business models based on its optimized GMP (manufacturing and quality control) technology for developing multiple cell and gene therapies: advanced biopharmaceutical contract development and manufacturing (CDMO), and development of next-generation cell and gene therapy new drugs. In the advanced biopharmaceutical CDMO business, the company implements clients' various advanced biopharmaceutical source technologies (IP) into drug-grade finished products using its GMP system, which requires GMP production technology, a CDMO business management system, multi-item process technology, a multi-item production workforce, production know-how, and GMP facilities. Because there is currently no standardized production process for advanced biopharmaceuticals, customized production process development and optimization are required for each item.
Representative Director Jang Jonguk
Founded March 21, 2018
Corporation Type KOSDAQ
Industry Classification Manufacture of medicinal chemicals
Corporate number 11011-6693918
Business number 360-86-01147
Phone Number 02-6205-8050
Fax Number
Company Address 201 Songpa-daero, Songpa-gu, Seoul
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant